Government Restricts Manufacture, Sale and Distribution of Fixed Dose Combinations Containing Chlorpheniramine Maleate and Phenylephrine Hydrochloride for Use in Children Below Four Years

In a landmark regulatory move to protect pediatric health, the Government of India has extended restrictions on all Fixed Dose Combinations (FDCs) containing Chlorpheniramine Maleate and Phenylephrine Hydrochloride, mandating a clear age-specific warning against their use in children below four years. This notification, issued on 22 August 2026 under Section 26A of the Drugs and Cosmetics Act, 1940, represents a significant escalation from the earlier partial restriction vide S.O. 1717(E) dated 15 April 2025, which had applied only to certain FDCs. The decision follows evidence-based recommendations from the Expert Committee and the Drugs Technical Advisory Board (DTAB), the apex statutory body under the Drugs and Cosmetics Act that advises the Central and State Governments on technical matters arising from the administration of the Act. The mandatory warning — "Fixed Dose Combination shall not be used in children below four years of age" — must now appear on labels, package inserts, and all promotional literature, ensuring comprehensive information dissemination to healthcare providers and caregivers alike. The background to this decision lies in growing global and domestic concerns about the safety profile of cough and cold preparations in young children. Chlorpheniramine Maleate, a first-generation antihistamine, and Phenylephrine Hydrochloride, a decongestant, are commonly combined in over-the-counter pediatric formulations for symptomatic relief of cold and allergic conditions. However, pharmacovigilance data and international regulatory actions — notably the US FDA's 2008 advisory against use in children under 2 years and subsequent restrictions in Canada, UK, and Australia — have highlighted risks including sedation, respiratory depression, cardiac arrhythmias, and paradoxical excitation in young children. The DTAB's recommendation reflects a precautionary approach aligned with the principle of 'first, do no harm,' especially given the availability of safer alternatives such as saline nasal drops, hydration, and age-appropriate monotherapy under medical supervision. This regulatory action must be understood within the broader framework of India's evolving drug regulatory architecture. The Drugs and Cosmetics Act, 1940, amended multiple times including the 2008 amendment that strengthened penalties and introduced provisions for clinical trials, remains the cornerstone of pharmaceutical regulation. Section 26A empowers the Central Government to prohibit or restrict the manufacture, sale, or distribution of any drug in public interest — a provision that has been invoked previously for FDC bans (e.g., the 2016 ban on 344 FDCs based on the Kokate Committee report). The current move demonstrates the government's increasing reliance on expert bodies like DTAB and the Expert Committee to ensure evidence-based policymaking, moving away from ad hoc decisions. Stakeholders involved span the regulatory, medical, industrial, and consumer domains. The Central Drugs Standard Control Organisation (CDSCO), under the Ministry of Health and Family Welfare, is the implementing authority. State Drug Controllers will enforce compliance at the ground level. Pharmaceutical manufacturers — particularly those producing pediatric cough-cold syrups — must reformulate, relabel, or withdraw products, impacting a significant market segment. Pediatricians and pharmacists play a crucial role in guiding parents toward safer alternatives. Most importantly, the decision directly affects millions of parents and caregivers, especially in rural and semi-urban areas where self-medication with OTC syrups is prevalent due to limited access to pediatricians. The significance for India is multifold. Socially, it addresses a critical patient safety gap in a country where irrational FDC use has been a long-standing concern — the 2016 ban on 344 FDCs was a watershed moment, and this notification continues that trajectory. Economically, while short-term disruption to manufacturers is inevitable, the long-term benefit lies in aligning Indian regulatory standards with global best practices, enhancing the credibility of India's pharmaceutical industry — the 'pharmacy of the world' — which exports to over 200 countries. Politically, it signals the government's commitment to public health, particularly child health, resonating with Sustainable Development Goal 3.2 (ending preventable deaths of newborns and children under 5). Constitutionally, while health is a State subject (List II, Entry 6), drug regulation falls under Concurrent List (Entry 19), enabling Central legislation like the Drugs and Cosmetics Act. The use of Section 26A exemplifies cooperative federalism in action, as States enforce Central standards. Broader themes emerge: the tension between commercial interests and public health, the role of expert bodies in governance, and the challenge of enforcing regulations in a fragmented healthcare system. The notification also underscores the importance of pharmacovigilance — India's Pharmacovigilance Programme of India (PvPI), coordinated by the Indian Pharmacopoeia Commission, must now monitor adverse drug reactions (ADRs) related to these FDCs more vigilantly. Future implications are significant. We may see further age-based restrictions on other FDCs, especially those containing codeine, dextromethorphan, or other CNS-acting agents. The government might strengthen the New Drugs and Clinical Trials Rules, 2019, to mandate pediatric studies for drugs intended for children. Digital enforcement — using the CDSCO's SUGAM portal for tracking compliance — could be enhanced. Ultimately, this move could catalyze a shift from symptomatic polypharmacy to evidence-based, age-appropriate pediatric prescribing, reducing antimicrobial resistance and adverse events. For aspirants, this case study exemplifies the intersection of public health policy, regulatory law, and governance — a recurring theme in UPSC, State PSCs, and other competitive examinations.